These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 6261943)

  • 21. Dianhydrogalactitol (NSC-132313): phase II study in solid tumors.
    de Jager R; Brugarolas A; Hansen H; Cavalli F; Ryssel H; Siegenthaler P; Clarysse A; Renard J; Kenis Y; Alberto P
    Eur J Cancer (1965); 1979 Jul; 15(7):971-4. PubMed ID: 385328
    [No Abstract]   [Full Text] [Related]  

  • 22. Phase II evaluation of aclarubicin in lung cancer: a Southeastern Cancer Study Group Trial.
    Kramer BS; Birch R; Gockerman JP; Greco A; Prestridge K
    Cancer Treat Rep; 1986 Jun; 70(6):803-4. PubMed ID: 3015404
    [No Abstract]   [Full Text] [Related]  

  • 23. Phase II evaluation of dianhydrogalactitol in the treatment of advanced non-squamous cervical carcinoma. A Gynecologic Oncology Group study.
    Stehman FB; Blessing JA; Homesley HD; Currie JL; Yordan EL
    Invest New Drugs; 1984; 2(3):331-3. PubMed ID: 6511240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II evaluation of galactitol in head and neck cancer: a Southwest Oncology Group Study.
    Haas CD; Lehane D; Bottomley R
    Med Pediatr Oncol; 1983; 11(4):281-3. PubMed ID: 6888328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of advanced non-small cell lung cancer with bisantrene.
    Fuks JZ; Van Echo DA; Garbino C; Kasdorf H; Aisner J
    Cancer Treat Rep; 1983 Jun; 67(6):597-8. PubMed ID: 6305499
    [No Abstract]   [Full Text] [Related]  

  • 26. Phase II evaluation of vindesine in non-small cell bronchogenic carcinoma.
    Hutcheon AW; Palmer JB; Pratt MA; Clark RA
    Cancer Treat Rep; 1983 Nov; 67(11):1041-2. PubMed ID: 6315231
    [No Abstract]   [Full Text] [Related]  

  • 27. Phase II trial of galactitol 1,2:5,6-dianhydro (NSC 132313) in the treatment of advanced gynecologic malignancies: a Gynecologic Oncology Group study.
    Stehman FB; Blom J; Blessing JA; Ehrlich CE; Mangan C
    Gynecol Oncol; 1983 Jun; 15(3):381-90. PubMed ID: 6862293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Four-drug combination chemotherapy in extensive non-small cell lung cancer: a Southwest Oncology Group Pilot Study.
    Livingston RB; Mira J; O'Bryan RM
    Cancer Treat Rep; 1981; 65(1-2):143-4. PubMed ID: 6164484
    [No Abstract]   [Full Text] [Related]  

  • 29. [Phase II study of vindesine in patients with carcinoma of the lung and metastatic pulmonary tumor].
    Shibuya M; Saijo N; Shimizu E; Eguchi K; Shinkai T; Tominaga K; Shimabukuro Z
    Gan To Kagaku Ryoho; 1982 Oct; 9(10):1808-13. PubMed ID: 6307176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study on DON in patients with previously treated advanced lung cancer.
    Eagan RT; Frytak S; Nichols WC; Creagan ET; Ingle JN
    Cancer Treat Rep; 1982 Aug; 66(8):1665-6. PubMed ID: 6286122
    [No Abstract]   [Full Text] [Related]  

  • 31. 5-FU in the treatment of small cell anaplastic carcinoma of the lung: a phase II trial.
    Havsteen H; Sörenson S; Rørth M; Dombernowsky P; Hansen HH
    Cancer Treat Rep; 1981; 65(1-2):123-5. PubMed ID: 6261945
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II trial of methylglyoxal-bis-(guanylhydrazone) in non-small-cell lung cancer.
    Chapman R; Kelsen D; Gralla R; Itri L; Casper E; Young C; Golbey R
    Cancer Clin Trials; 1981; 4(4):389-91. PubMed ID: 6274532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of single-agent cisplatin in the management of non-small cell carcinoma of the lung: a Southwest Oncology Group Study.
    Panettiere FJ; Vance RB; Stuckey WJ; Coltman CA; Costanzi JJ; Chen TT
    Cancer Treat Rep; 1983 Apr; 67(4):399-400. PubMed ID: 6682701
    [No Abstract]   [Full Text] [Related]  

  • 34. Phase II studies of dianhydrogalactitol and VP-16-213 in colorectal cancer.
    Perry MC; Moertel CG; Schutt AJ; Reitemeier RJ; Hahn RG
    Cancer Treat Rep; 1976 Sep; 60(9):1247-50. PubMed ID: 797447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II trial of cisplatin in small cell carcinoma of the lung.
    Levenson RM; Ihde DC; Huberman MS; Cohen MH; Bunn PA; Minna JD
    Cancer Treat Rep; 1981; 65(9-10):905-7. PubMed ID: 6268297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Results of a phase II protocol for evaluation of new chemotherapeutic regimens in patients with inoperable non-small cell lung carcinoma (EST-2575, generation I).
    Creech RH; Mehta CR; Cohen M; Donavan M; Sponzo R; Mason BA; Skeel RT; Ahmed F; Creaven PJ; Lerner HJ; Foelsch E
    Cancer Treat Rep; 1981; 65(5-6):431-8. PubMed ID: 6263476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preliminary study of the combination, dianhydrogalactitol, cis-diaminedichloroplatinum (II), and VP-16-213 in patients with advanced cancer.
    Creagan ET; Eagan RT; Kvols LK
    Oncology; 1981; 38(5):260-1. PubMed ID: 7196561
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemotherapy for advanced adenocarcinoma and squamous cell carcinoma of the lung with etoposide and cisplatin.
    Dhingra HM; Valdivieso M; Booser DJ; Umsawasdi T; Carr DT; Chiuten DF; Murphy WK; Issell BF; Spitzer G; Farha P
    Cancer Treat Rep; 1984 Apr; 68(4):671-3. PubMed ID: 6538811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vindesine in the treatment of squamous cell carcinoma, adenocarcinoma, and large cell carcinoma of the lung.
    Osterlind K; Hørbov S; Dombernowsky P; Rørth M; Hansen HH
    Cancer Treat Rep; 1982 Feb; 66(2):305-9. PubMed ID: 7055816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dianhydrogalactitol and radiation therapy. Treatment of supratentorial glioma.
    Eagan RT; Childs DS; Layton DD; Laws ER; Bisel HF; Holbrook MA; Fleming TR
    JAMA; 1979 May; 241(19):2046-50. PubMed ID: 219269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.